- Home
- KPRX vs FTFT Comparison
KPRX vs FTFT Comparison
Compare KPRX & FTFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- FTFT
- Stock Information
- Founded
- KPRX 1998
- FTFT N/A
- Country
- KPRX United States
- FTFT United States
- Employees
- KPRX N/A
- FTFT N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- FTFT Business Services
- Sector
- KPRX Health Care
- FTFT Consumer Discretionary
- Exchange
- KPRX Nasdaq
- FTFT Nasdaq
- Market Cap
- KPRX 9.2M
- FTFT 11.0M
- IPO Year
- KPRX N/A
- FTFT N/A
- Fundamental
- Price
- KPRX $2.52
- FTFT $2.11
- Analyst Decision
- KPRX Strong Buy
- FTFT
- Analyst Count
- KPRX 1
- FTFT 0
- Target Price
- KPRX $10.00
- FTFT N/A
- AVG Volume (30 Days)
- KPRX 52.9K
- FTFT 90.1K
- Earning Date
- KPRX 11-07-2025
- FTFT 11-18-2025
- Dividend Yield
- KPRX N/A
- FTFT N/A
- EPS Growth
- KPRX N/A
- FTFT N/A
- EPS
- KPRX N/A
- FTFT N/A
- Revenue
- KPRX N/A
- FTFT $2,368,206.00
- Revenue This Year
- KPRX N/A
- FTFT N/A
- Revenue Next Year
- KPRX N/A
- FTFT N/A
- P/E Ratio
- KPRX N/A
- FTFT N/A
- Revenue Growth
- KPRX N/A
- FTFT N/A
- 52 Week Low
- KPRX $2.21
- FTFT $1.01
- 52 Week High
- KPRX $4.18
- FTFT $5.70
- Technical
- Relative Strength Index (RSI)
- KPRX 42.43
- FTFT 48.41
- Support Level
- KPRX $2.21
- FTFT $1.99
- Resistance Level
- KPRX $2.80
- FTFT $2.24
- Average True Range (ATR)
- KPRX 0.15
- FTFT 0.16
- MACD
- KPRX -0.03
- FTFT -0.01
- Stochastic Oscillator
- KPRX 41.89
- FTFT 27.91
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.